

**IN THE CLAIMS:**

1-104. (Cancelled)

105. **(Previously Presented)** A method of treating neoplastic disease in a human or animal patient comprising administering to the patient an anti-neoplastic effective amount of a composition comprising as the sole pharmaceutically active components:

- (a) copper gluconate or copper orotate;
- (b) sodium salicylate;
- (c) vitamin C;
- (d) manganese gluconate or manganese orotate ; and optionally one or more of:
- (e) iron gluconate or iron orotate;
- (f) sublimed sulphur; and
- (g) zinc gluconate or zinc orotate.

106. **(Currently Amended)** The method of treating neoplastic disease in a human or animal patient according to Claim 105 wherein the composition comprises as the sole pharmaceutically active components (a)-(e) and optionally one or both of (f)-(g) ~~contains iron gluconate or iron orotate.~~

107. (Cancelled)

108. **(Currently Amended)** The method of treating neoplastic disease in a human or animal patient according to Claim 105 wherein the composition comprises as the sole pharmaceutically active components (a)-(d) and (g) and optionally one or both of (e) and (f) ~~contains zinc gluconate or zinc orotate.~~

109-123. **(Cancelled)**

124. **(Currently Amended)** The method of treating neoplastic disease in a human or animal patient according to Claim 105 wherein ~~the composition comprises:~~

the copper gluconate or copper orotate is present in an amount of 15 to 60 parts by weight if copper gluconate, or equivalent amount of active ingredient if copper orotate ~~when a physiologically acceptable source of assimilable copper other than copper gluconate is used;~~

the sodium salicylate is present in an amount of 300 to 600 parts by weight sodium salicylate, or equivalent amount of active ingredient when salicylic acid or another alkali or alkaline earth metal salt thereof other than sodium salicylate is used;

the vitamin C is present in an amount of 200 to 1000 parts by weight vitamin C,  
and

the manganese gluconate or manganese orotate is present in an amount of from 15 to 60 parts by weight [[of]] if manganese gluconate, or equivalent amount of active ingredient if manganese orotate ~~when a physiologically acceptable source of assimilable manganese other than manganese gluconate is used,~~

the parts by weight referred to being based on the total weight of these ingredients in the composition.

125. **(Currently Amended)** The method of treating neoplastic disease in a human or animal patient according to Claim 124 wherein ~~the composition comprises:~~  
the copper gluconate or copper orotate is present in an amount of 15 to 40  
parts by weight if copper gluconate, or equivalent amount of active ingredient if copper  
orotate ~~when a physiologically acceptable source of assimilable copper other than~~  
~~copper gluconate is used;~~  
the sodium salicylate is present in an amount of 300 to 400 parts by weight  
~~sodium salicylate, or equivalent amount of active ingredient when salicylic acid or~~  
~~another alkali or alkaline earth metal salt thereof other than sodium salicylate is used;~~  
and

the vitamin C is present in an amount of 300 to 500 parts by weight ~~vitamin C.~~

126. **(Cancelled)**

127. **(Currently Amended)** The method of treating neoplastic disease in a human or animal patient according to Claim 124 wherein sublimed sulphur is present  
in an amount of ~~the composition further comprises~~ 15 to 60 parts by weight of sulphur.

128. **(Currently Amended)** The method of treating neoplastic disease in a human or animal patient according to Claim 124 wherein the iron gluconate or iron orotate is present in an amount of ~~composition further comprises~~ 15 to 60 parts by weight if iron gluconate, or equivalent amount of active ingredient if iron orotate ~~when a physiologically acceptable source of assimilable iron other than iron gluconate is used,~~ and the sublimed sulphur is present in an amount of 15 to 60 parts by weight of sulphur.

129. **(Currently Amended)** The method of treating neoplastic disease in a human or animal patient according to Claim 124 wherein the zinc gluconate or zinc orotate is present in an amount of ~~composition further comprises~~ 15 to 60 parts by weight if zinc gluconate, or equivalent amount of active ingredient if zinc orotate ~~when a physiologically acceptable source of assimilable zinc other than zinc gluconate is used.~~

130. **(Currently Amended)** The method of treating neoplastic disease in a human or animal patient according to Claim 124 wherein ~~the composition comprises:~~

(a) the copper gluconate or copper orotate is present in an amount of 15 to 40 parts by weight if copper gluconate, or equivalent amount of active ingredient if copper orotate ~~when a physiologically acceptable source of assimilable copper other than copper gluconate is used;~~

(b) the sodium salicylate is present in an amount of 350 parts by weight ~~sodium salicylate, or equivalent amount of active ingredient when salicylic acid or another alkali or alkaline earth metal salt thereof other than sodium salicylate is used;~~

(c) the vitamin C is present in an amount of 400 parts by weight ~~vitamin C,~~

and

(d) the manganese gluconate or manganese orotate is present in an amount of 15 to 40 parts by weight [[of]] if manganese gluconate, or equivalent amount of active ingredient if manganese orotate ~~when a physiologically acceptable source of assimilable manganese other than manganese gluconate is used.~~

131. (Cancelled)

132. (Currently Amended) The method of treating neoplastic disease in a human or animal patient according to Claim 124 130 wherein the sublimed sulphur is present in an amount of ~~composition further comprises~~ 15 to 60 parts by weight of sulphur.

133. (Currently Amended) The method of treating neoplastic disease in a human or animal patient according to Claim 124 130 wherein the iron gluconate or iron orotate is present in an amount of ~~composition further comprises~~ 15 to 40 parts by weight if iron gluconate, or equivalent amount of active ingredient if iron orotate ~~when a physiologically acceptable source of assimilable iron other than iron gluconate is used,~~ and the sublimed sulphur is present in an amount of 15 to 40 parts by weight of sulphur.

134. **(Currently Amended)** The method of treating neoplastic disease in a human or animal patient according to Claim ~~124~~ 130 wherein the zinc gluconate or zinc orotate is present in an amount of ~~composition further comprises~~ 15 to 40 parts by weight if zinc gluconate, or equivalent amount of active ingredient if zinc orotate ~~when a physiologically acceptable source of assimilable zinc other than zinc gluconate is used.~~

135. **(Previously Presented)** The method of treating neoplastic disease in a human or animal patient according to Claim 105 wherein the composition is in the form of an orally administrable unit dosage form.

136-164. **(Cancelled)**

165. **(Currently Amended)** The method of treating neoplastic disease in a human or animal patient according to claim 105 wherein the composition comprises as the sole pharmaceutically active components (a)-(d) and (f) and optionally one or both of (e) and (g) ~~contains sublimed sulphur.~~

166. **(Previously Presented)** The method of treating neoplastic disease in a human or animal patient according to claim 105 wherein the composition comprises as the sole pharmaceutically active components (a)-(d).